Keywords
How to Cite
Abstract
Considering the growing impact of type 2 diabetes on global public health, there is a justified need to explore effective therapeutic approaches. This study aimed to conduct a comparative analysis between alpha-glucosidase inhibitors and DPP-4 inhibitors, both used in the management of type 2 diabetes. To this end, a qualitative bibliographic review was conducted, covering multiple languages, using databases such as Scielo, Google Scholar, scientific journals, repositories, and virtual libraries. Inclusion and exclusion criteria were applied to select relevant studies that addressed the efficacy, side effects, mechanisms of action, and impact on glycemic control of these inhibitors. It was observed that DPP-4 inhibitors, such as Sitagliptin and Saxagliptin, are effective in reducing fasting glucose and glycated hemoglobin (HbA1C), in addition to presenting a favorable safety profile. On the other hand, alpha-glucosidase inhibitors, such as Acarbose, stand out in reducing postprandial glucose but are frequently associated with adverse gastrointestinal effects such as flatulence and diarrhea. It is concluded that both classes of drugs have their specific advantages, with DPP-4 inhibitors being more effective in reducing HbA1C and better tolerated, while alpha-glucosidase inhibitors are particularly useful for controlling postprandial glucose. The choice of treatment should be individualized, considering the efficacy, tolerability, and specific needs of patients. Future studies may explore therapeutic combinations to maximize benefits and minimize adverse effects, as well as investigate treatments based on genetic characteristics and specific biomarkers for a more personalized management of type 2 diabetes.
References
AHRÉN, Bo; FOLEY, James E. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia, v. 59, n. 5, p. 907-917, 2016.
ANDERSEN, Emilie S.; DEACON, Carolyn F.; HOLST, Jens J. Do we know the true mechanism of action of the DPP‐4 inhibitors?. Diabetes, Obesity and Metabolism, v. 20, n. 1, p. 34-41, 2018.
BERGER, Joel P. et al. A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice. Endocrinology, diabetes & metabolism, v. 1, n. 1, p. e00002, 2017.
BLICKLE, J. F.; ANDRES, E.; BROGARD, J. M. Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors. La Revue de Medecine Interne, v. 20, p. 379s-383s, 1999.
Brasil. Ministério da Saúde. OPAS. Avaliação do Plano de Reorganização da Atenção à Hipertensão Arterial e ao Diabetes Mellitus no Brasil. Brasília: Ministério da Saúde; 2004.
CAI, Xiaoling et al. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. Endocrine, v. 50, p. 590-597, 2015.
Ceriello, A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54(1):1-7.
CREPALDI, G. et al. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. Journal of endocrinological investigation, v. 30, p. 610-614, 2007.
DEACON, Carolyn F. Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism, v. 13, n. 1, p. 7-18, 2011.
EDELMAN, Steven V. Importance of glucose control. Medical Clinics of North America, v. 82, n. 4, p. 665-687, 1998.
GASTER, Barak; HIRSCH, Irl B. The effects of improved glycemic control on complications in type 2 diabetes. Archives of Internal Medicine, v. 158, n. 2, p. 134-140, 1998.
GRANT, Abigail Kennedy; GOLDEN, Lauren. Technological advancements in the management of type 2 diabetes. Current diabetes reports, v. 19, p. 1-5, 2019.
GUERRON, Alfredo Daniel; DAVIS, Georgia M.; PASQUEL, Francisco J. Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. Endocrinology and Metabolism Clinics, v. 50, n. 3, p. 457-474, 2021.
HATTORI, Akiko et al. Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, v. 126, p. 138-143, 2017.
KRISTIN, Erna. Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus. Journal of Medical Sciences, v. 48, n. 2, p. 1-9, 2016.
KUROZUMI, Akira et al. Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. Journal of Diabetes Investigation, v. 4, n. 4, p. 393-398, 2013.
LEBOVITZ, Harold E. Alpha-glucosidase inhibitors. Endocrinology and metabolism clinics of North America, v. 26, n. 3, p. 539-551, 1997.
LI, Zhaoliang et al. Head-to-Head comparison of the hypoglycemic efficacy and safety between dipeptidyl peptidase-4 inhibitors and α-glucosidase inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Frontiers in pharmacology, v. 10, p. 777, 2019.
MAZZOLA, Nissa. Review of current and emerging therapies in type 2 diabetes mellitus. American Journal of Managed Care, v. 18, n. 1, p. S17, 2012.
MIN, Se Hee et al. Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta‐analysis. Journal of diabetes investigation, v. 9, n. 4, p. 893-902, 2018.
MU, Xinxin et al. Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review. Critical Reviews in Food Science and Nutrition, p. 1-13, 2023.
NAKAMURA, Kazufumi et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovascular Diabetology, v. 13, p. 1-10, 2014.
OMAR, Bilal; AHRÉN, Bo. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes, v. 63, n. 7, p. 2196-2202, 2014.
OLIVEIRA, M. S. et al. Diabetes Mellitus tipo 2 - uma revisão abrangente sobre a etiologia, epidemiologia, fisiopatologia, diagnóstico e tratamento. Brazilian Journal of Health Review, v. 6, n. 5, p. 24074–24085, 6 out. 2023.
PI-SUNYER, F. Xavier. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgraduate medicine, v. 120, n. 2, p. 5-17, 2008.
PEREIRA, L. S. Relação entre gravidade da síndrome de apneia obstrutiva do sono e diabetes tipo 2. 2021. 28 f. Trabalho de Conclusão de Curso (Residência Médica em Otorrinolaringologia) – Hospital do Servidor Público Municipal, São Paulo, 2021.
PIRES, M. M. et al. Diabetes mellitus tipo 2 - uma revisão de literatura. Brazilian Journal of Health Review, v. 7, n. 2, p. e69219–e69219, 26 abr. 2024.
RAPTIS, S. A.; DIMITRIADIS, G. D. Oral hypoglycemic agents: insulin secretagogues, α-glucosidase inhibitors and insulin sensitizers. Experimental and Clinical Endocrinology & Diabetes, v. 109, n. Suppl 2, p. S265-S287, 2001.
SARABU, Ramakanth; TILLEY, Jefferson. Recent advances in therapeutic approaches to Type 2 Diabetes. Annu. Rep. Med. Chem, v. 39, p. 39-56, 2004.
SCHEEN, A. J. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, v. 38, n. 2, p. 89-101, 2012.
SOCIEDADE BRASILEIRA DE DIABETES. Diretrizes da Sociedade Brasileira de Diabetes 2015-2016. São Paulo: Sociedade Brasileira de Diabetes, 2016. 348 p.
Sociedade Brasileira de Diabetes. Consenso brasileiro sobre diabetes 2002: Diagnóstico e classificação do diabetes Mellitus e tratamento do diabetes Mellitus do tipo 2. Rio de Janeiro: Diagraphic; 2003.
TAHRANI, Abd A. et al. Management of type 2 diabetes: new and future developments in treatment. The Lancet, v. 378, n. 9786, p. 182-197, 2011.
THORNBERRY, Nancy A.; GALLWITZ, Baptist. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research Clinical endocrinology & metabolism, v. 23, n. 4, p. 479-486, 2009.
VAN DE LAAR, Floris A. et al. Alpha‐glucosidase inhibitors for type 2 diabetes mellitus. Cochrane database of systematic reviews, n. 2, 2005.
DOS SANTOS, Vitor Cardoso et al. Diabetes Mellitus Tipo 2-aspectos epidemiológicos, fisiopatológicos e manejo terapêutico. Brazilian Journal of Development, v. 9, n. 3, p. 9737-9749, 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Bruno de Vasconcelos Braga, João Vitor Cunha Lima Paranhos, Matheus Cortizo Carballal, Iasmim Camila Chaves Pessoa, Ariana Nicol Eugenio Vela, Leonardo Barroso de Moraes Santos , Arnóbio Ângelo de Mariz Neto, Maria Eduarda de Melo Silva Pessoa, Tamile Machado Carneiro, Rigoberto Rodrigues de Lima Filho, Ana Paula Guadagnin, Anderson Henrique Araquam da Silva Almeida, Arthur Emil Karlburger, Bianca Borges Pinto, Thamiris Carvalho de Souza, Dinarthe Dantas da Fonseca Junior, Allana Carlos Torres, Alana Moury Fernandes Leite da Silva, Gabriel Santos da Silva, Jéssica Bittencourt Lisbôa, Keyze Mirelly Carneiro da Silva Ferreira, Mariana da Silva Carvalho Senna, Laura Stefani Da Costa Neres, Lisiane Nobuko Nagabe, Nathalia Brito Dumas, Sofia Dutra Morais